0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Transferrin R

Transferrin R

Brief Information

Name:Transferrin receptor protein 1
Target Synonym:TFRC,T9,sTfR,Transferrin receptor protein 1,TR,Transferrin Receptor,P90,Transferrin Receptor (P90, CD71),CD71 Antigen,IMD46,CD71,TfR1,Trfr,TfR
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

TFR-C524a-ELISA
Cynomolgus Transferrin R, His TagCynomolgus Transferrin R, His Tag (Cat. No. TFR-C524a) ELISA bioactivity

Immobilized Human Transferrin, His Tag (Cat. No. TRN-H4229) at 5 μg/mL (100 μL/well) can bind Cynomolgus Transferrin R, His Tag (Cat. No. TFR-C524a) with a linear range of 0.2-6 ng/mL (QC tested).

TFR-H82E5-MALS-HPLC
Biotinylated Human Transferrin R, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human Transferrin R, His,Avitag(Cat. No. TFR-H82E5) was more than 90% and the molecular weight of this protein is around 160-180 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human Transferrin R, His,AvitagBiotinylated Human Transferrin R, His,Avitag (Cat. No. TFR-H82E5) ELISA bioactivity

Immobilized Human Transferrin, His Tag (Cat. No. TRN-H4229) at 2 μg/mL (100 μL/well) can bind Biotinylated Human Transferrin R, His,Avitag (Cat. No. TFR-H82E5) with a linear range of 2-63 ng/mL (QC tested).

Synonym Name

CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90

Background

CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CX-2029 CX-2029 Phase 2 Clinical Cytomx Therapeutics Head and Neck Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop